CO5690570A2 - Nueva combinacion sinergistica que comprende roflumilast y formoterol - Google Patents

Nueva combinacion sinergistica que comprende roflumilast y formoterol

Info

Publication number
CO5690570A2
CO5690570A2 CO05062787A CO05062787A CO5690570A2 CO 5690570 A2 CO5690570 A2 CO 5690570A2 CO 05062787 A CO05062787 A CO 05062787A CO 05062787 A CO05062787 A CO 05062787A CO 5690570 A2 CO5690570 A2 CO 5690570A2
Authority
CO
Colombia
Prior art keywords
formoterol
roflumilast
daily dose
combined use
combination including
Prior art date
Application number
CO05062787A
Other languages
English (en)
Spanish (es)
Inventor
Rolf Beume
Daniela Bundschuh
Norbert Kolassa
Christian Weimar
Degenhard Marx
Original Assignee
Altana Pharma Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altana Pharma Ag filed Critical Altana Pharma Ag
Publication of CO5690570A2 publication Critical patent/CO5690570A2/es

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44Non condensed pyridines; Hydrogenated derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/16Amides, e.g. hydroxamic acids
    • A61K31/165Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pulmonology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicinal Preparation (AREA)
CO05062787A 2002-11-27 2005-06-27 Nueva combinacion sinergistica que comprende roflumilast y formoterol CO5690570A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP02026505 2002-11-27

Publications (1)

Publication Number Publication Date
CO5690570A2 true CO5690570A2 (es) 2006-10-31

Family

ID=32338002

Family Applications (1)

Application Number Title Priority Date Filing Date
CO05062787A CO5690570A2 (es) 2002-11-27 2005-06-27 Nueva combinacion sinergistica que comprende roflumilast y formoterol

Country Status (31)

Country Link
US (1) US20060142308A1 (enExample)
EP (1) EP1567139B1 (enExample)
JP (1) JP2006508994A (enExample)
KR (1) KR101071798B1 (enExample)
CN (1) CN100346777C (enExample)
AT (1) ATE399543T1 (enExample)
AU (1) AU2003292120B2 (enExample)
BR (1) BR0316451A (enExample)
CA (1) CA2506962C (enExample)
CO (1) CO5690570A2 (enExample)
CY (1) CY1110369T1 (enExample)
DE (1) DE60321953D1 (enExample)
DK (1) DK1567139T3 (enExample)
EA (1) EA009935B1 (enExample)
ES (1) ES2309357T3 (enExample)
HR (1) HRP20050579B1 (enExample)
IL (1) IL168308A (enExample)
IS (1) IS2575B (enExample)
MA (1) MA27539A1 (enExample)
ME (1) ME00489B (enExample)
MX (1) MXPA05005437A (enExample)
NO (1) NO334247B1 (enExample)
NZ (1) NZ540659A (enExample)
PL (1) PL216752B1 (enExample)
PT (1) PT1567139E (enExample)
RS (1) RS51081B (enExample)
SI (1) SI1567139T1 (enExample)
TN (1) TNSN05131A1 (enExample)
UA (1) UA83018C2 (enExample)
WO (1) WO2004047829A1 (enExample)
ZA (1) ZA200503308B (enExample)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MY140561A (en) * 2002-02-20 2009-12-31 Nycomed Gmbh Dosage form containing pde 4 inhibitor as active ingredient
PL1606261T3 (pl) 2003-03-10 2010-04-30 Astrazeneca Ab Nowy sposób przygotowania roflumilastu
EP1861074B1 (en) * 2005-03-16 2013-04-24 Takeda GmbH Taste masked dosage form containing roflumilast
DE102005030733A1 (de) * 2005-07-01 2007-01-04 Boehringer Ingelheim Pharma Gmbh & Co. Kg Neue Arzneimittelkombinationen zur Behandlung von Atemwegserkrankungen enthaltend langwirksame Beta-2-Agonisten und wenigstens einen weiteren Wirkstoff
EP2359826B1 (en) * 2006-07-05 2013-10-30 Takeda GmbH Combination of HMG-COA reductase inhibitor rosuvastatin with a phosphodiesterase 4 inhibitor, such as roflumilast, roflumilast-N-oxide for the treatment of inflammatory pulmonary diseases
WO2013077830A1 (en) * 2011-11-25 2013-05-30 Mahmut Bilgic Synergistilly active combinations of roflumilast and carmoterol
US20130172303A1 (en) * 2012-01-03 2013-07-04 Forest Laboratories Holdings Ltd. Roflumilast compositions for the treatment of copd
WO2014115127A1 (en) 2013-01-28 2014-07-31 Incozen Therapeutics Pvt. Ltd. Methods of treating autoimmune, respiratory and inflammatory disorders by inhalation of roflumilast n-oxide
CN104800214A (zh) * 2014-01-27 2015-07-29 成都英诺新科技有限公司 一种罗氟司特吸入气雾剂复方及制备方法

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795564A (en) * 1991-04-05 1998-08-18 Sepracor, Inc. Methods and compositions for treating pulmonary disorders using optically pure (R,R)-formoterol
CZ290266B6 (cs) * 1993-07-02 2002-06-12 Byk Gulden Lomberg Chemische Fabrik Gmbh Substituované benzamidy, způsob jejich výroby a farmaceutické prostředky s jejich obsahem
BR9807399B1 (pt) * 1997-02-17 2011-04-19 composição para o tratamento de sìndrome da angústia respiratória infantil (irds) ou sìndrome da angústia respiratória aguda (ards) compreendendo 3-(ciclopropilmetóxi)-n-(3,5-dicloro-4-piridinil)-4-(difl uorometóxi) benzamida e tensoativo do pulmão, e seu uso.
US6624181B1 (en) * 1997-02-28 2003-09-23 Altana Pharma Ag Synergistic combination
US6333354B1 (en) * 1997-02-28 2001-12-25 Byk Gulden Lomberg Chemische Fabrik Gmbh Synergistic combination of PDE inhibitors and adenylate cyclase agonists or guanyl cyclyse agonists
NZ527232A (en) * 1998-08-26 2005-03-24 Smithkline Beecham Corp A composition contaning a PDE 4 inhibitor and a beta adrenergic bronchodilator useful for treating pulmonary diseases
US6303145B2 (en) * 1999-05-10 2001-10-16 Sepracor Inc. (S,R) formoterol methods and compositions
EP1671651B1 (en) * 1999-08-21 2009-11-11 Nycomed GmbH Synergistic combination of pumafentrine and salmeterol
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
JP4143413B2 (ja) * 2001-03-22 2008-09-03 グラクソ グループ リミテッド β2−アドレナリン受容体アゴニストとしてのホルムアニリド誘導体
ATE411334T1 (de) * 2001-04-30 2008-10-15 Glaxo Group Ltd Antiphlogistische 7.beta.-carbothioate esterderivate von androstan mit einer 17.alpha.- zyklischen estergruppe

Also Published As

Publication number Publication date
DK1567139T3 (da) 2008-11-03
MXPA05005437A (es) 2005-08-03
EA200500774A1 (ru) 2005-12-29
IL168308A (en) 2010-12-30
WO2004047829A1 (en) 2004-06-10
PT1567139E (pt) 2008-10-01
NO334247B1 (no) 2014-01-20
CN100346777C (zh) 2007-11-07
KR20050085104A (ko) 2005-08-29
CA2506962A1 (en) 2004-06-10
KR101071798B1 (ko) 2011-10-11
CY1110369T1 (el) 2015-04-29
JP2006508994A (ja) 2006-03-16
AU2003292120A1 (en) 2004-06-18
ES2309357T3 (es) 2008-12-16
HRP20050579A2 (hr) 2006-04-30
EA009935B1 (ru) 2008-04-28
CA2506962C (en) 2012-01-03
IS2575B (is) 2010-02-15
UA83018C2 (uk) 2008-06-10
ME00489B (me) 2011-10-10
MA27539A1 (fr) 2005-09-01
NO20052999L (no) 2005-06-17
BR0316451A (pt) 2005-10-11
HRP20050579B1 (hr) 2014-01-31
ZA200503308B (en) 2006-11-29
CN1713903A (zh) 2005-12-28
EP1567139B1 (en) 2008-07-02
HK1081861A1 (en) 2006-05-26
PL216752B1 (pl) 2014-05-30
AU2003292120B2 (en) 2010-01-21
DE60321953D1 (de) 2008-08-14
US20060142308A1 (en) 2006-06-29
IS7898A (is) 2005-06-20
TNSN05131A1 (en) 2007-05-14
SI1567139T1 (sl) 2008-12-31
EP1567139A1 (en) 2005-08-31
RS51081B (sr) 2010-10-31
RS20050382A (sr) 2007-08-03
WO2004047829A8 (en) 2005-06-30
ATE399543T1 (de) 2008-07-15
PL377732A1 (pl) 2006-02-06
NZ540659A (en) 2007-05-31

Similar Documents

Publication Publication Date Title
CU23468B7 (es) Forma de dosificación de pramipexol en una dosis única diaria
BR0108730A (pt) Sistema, dispositivo e método para administração de uma droga, bocal de um dispositivo de administração de droga, dispositivo para administração de doses unitárias múltiplas de uma droga, métodos para preparação de um sistema de administração de droga e de uma formulação de droga e para tratamento de um paciente que necessita de doses múltiplas de uma droga, formulação de droga e multiparticulados
ES2123576T3 (es) Medicamentos.
ES2162927T3 (es) Formulacion para la aplicacion por inhalacion.
AR065579A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
AR101593A2 (es) Formulación superfina de formoterol
EA200802012A1 (ru) Фармацевтические препараты в форме раствора для дозирующих ингаляторов под давлением
CO5611092A2 (es) Formulacion superfina de formoterol
CO6150188A2 (es) Uso de teencteplasa para tratar un ictus isquemico agudo
CO6220969A2 (es) Adminsitracion semanal de inhibidores de peptidasa de dipeptidilo
AR065580A1 (es) Mejoras en composiciones medicinales o relativas a las mismas
BR112017026417B1 (pt) Formulação para o tratamento de distúrbios da boca, garganta e vias respiratórias
RU2008119454A (ru) Лекарственное средство для защиты моторного нейрона у пациентов с боковым амиотрофическим склерозом
CO5690570A2 (es) Nueva combinacion sinergistica que comprende roflumilast y formoterol
AR046036A1 (es) Composiciones de risedronato y metodos para su uso
CO5540290A2 (es) Composicion que comprende un inhibidor de pde-4 y antagonista del receptor-hi y su uso en la manufactura de un medicamento para el tratamiento de enfermedades respiratorias
GB2430623A (en) Medicaments for treating chronic respiratory disease
ES2175663T3 (es) Composiciones farmaceuticas solidas que contienen miltefosina para administracion oral en el tratamiento de la leshmaniasis.
Elwood et al. Midazolam coinduction does not delay discharge after very brief propofol anaesthesia
JPH09500610A (ja) 経鼻芳香放出組成物
AR065139A1 (es) Medicamento para el tratamiento de la endometriosis
Ko et al. Effects of topical O24 essential oils on patients with fibromyalgia syndrome: a randomized, placebo controlled pilot study
MX384760B (es) Combinación farmacéutica sinérgica del enantiómero activo s-ketorolaco y gabapentina para el tratamiento del dolor neuropático.
UY26595A1 (es) Formulaciones de entecavir de dosis bajas y uso
KR860003018A (ko) 1-β-D-리보푸라노실-1,2,4-트리아졸-3-카르복사미드를 이용한 인체의 비루스성 질환의 의학적 치료방법

Legal Events

Date Code Title Description
FA Application withdrawn